Kevin DeGeeter
Stock Analyst at Oppenheimer
(1.74)
# 2,125
Out of 4,415 analysts
31
Total ratings
33.33%
Success rate
50.09%
Average return
Main Sectors:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $2.56 | +759.38% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $9.71 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $1.54 | +1,458.44% | 3 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $14.78 | +563.06% | 1 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $21.50 | +481.40% | 2 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | n/a | $3.14 | - | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | n/a | $10.85 | - | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $1.63 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | n/a | $0.27 | - | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | n/a | $296.21 | - | 1 | Aug 24, 2021 | |
| EXAS Exact Sciences | Maintains: Outperform | n/a | $62.07 | - | 1 | Jul 29, 2021 | |
| SNSE Sensei Biotherapeutics | Downgrades: Perform | n/a | $1.79 | - | 2 | Jun 29, 2021 | |
| RZLT Rezolute | Initiates: Outperform | n/a | $3.31 | - | 1 | May 27, 2021 | |
| CYCC Cyclacel Pharmaceuticals | Initiates: Outperform | $255 | $2.00 | +12,650.00% | 1 | Apr 30, 2021 | |
| EVAX Evaxion Biotech | Initiates: Outperform | $180 | $3.95 | +4,456.96% | 1 | Mar 2, 2021 | |
| DMTK DermTech | Initiates: Outperform | n/a | $0.63 | - | 1 | Jan 22, 2021 | |
| VCEL Vericel | Downgrades: Perform | n/a | $47.83 | - | 1 | Jan 11, 2021 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | n/a | $2.57 | - | 1 | Jan 5, 2021 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Perform | n/a | $23.47 | - | 1 | Dec 8, 2020 | |
| CLRB Cellectar Biosciences | Initiates: Outperform | n/a | $3.42 | - | 1 | Jul 1, 2020 | |
| BNGO Bionano Genomics | Initiates: Outperform | n/a | $0.95 | - | 1 | Apr 8, 2020 | |
| IDXG Interpace Biosciences | Maintains: Outperform | n/a | $1.36 | - | 1 | Jan 16, 2020 | |
| NVAX Novavax | Upgrades: Buy | n/a | $4.93 | - | 1 | Aug 9, 2017 | |
| MTEM Molecular Templates | Initiates: Buy | n/a | $1.67 | - | 1 | Aug 3, 2017 | |
| CDTX Cidara Therapeutics | Initiates: Buy | $225 | $12.51 | +1,698.56% | 1 | Apr 12, 2017 | |
| MYGN Myriad Genetics | Upgrades: Neutral | n/a | $19.47 | - | 1 | Feb 8, 2017 | |
| CDXS Codexis | Upgrades: Buy | n/a | $3.92 | - | 1 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $2.56
Upside: +759.38%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $9.71
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $1.54
Upside: +1,458.44%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $14.78
Upside: +563.06%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $21.50
Upside: +481.40%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.14
Upside: -
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.85
Upside: -
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $1.63
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.27
Upside: -
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: n/a
Current: $296.21
Upside: -
Exact Sciences
Jul 29, 2021
Maintains: Outperform
Price Target: n/a
Current: $62.07
Upside: -
Sensei Biotherapeutics
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $1.79
Upside: -
Rezolute
May 27, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.31
Upside: -
Cyclacel Pharmaceuticals
Apr 30, 2021
Initiates: Outperform
Price Target: $255
Current: $2.00
Upside: +12,650.00%
Evaxion Biotech
Mar 2, 2021
Initiates: Outperform
Price Target: $180
Current: $3.95
Upside: +4,456.96%
DermTech
Jan 22, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.63
Upside: -
Vericel
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $47.83
Upside: -
Taysha Gene Therapies
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.57
Upside: -
Rocket Pharmaceuticals
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $23.47
Upside: -
Cellectar Biosciences
Jul 1, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.42
Upside: -
Bionano Genomics
Apr 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.95
Upside: -
Interpace Biosciences
Jan 16, 2020
Maintains: Outperform
Price Target: n/a
Current: $1.36
Upside: -
Novavax
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $4.93
Upside: -
Molecular Templates
Aug 3, 2017
Initiates: Buy
Price Target: n/a
Current: $1.67
Upside: -
Cidara Therapeutics
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $12.51
Upside: +1,698.56%
Myriad Genetics
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $19.47
Upside: -
Codexis
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $3.92
Upside: -